Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corporation - Common Stock (NQ: BPMC )

90.84 +1.00 (+1.11%)
Streaming Delayed Price Updated: 9:44 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,508
Open 90.44
Bid (Size) 90.32 (2)
Ask (Size) 91.18 (5)
Prev. Close 89.84
Today's Range 90.44 - 90.84
52wk Range 80.67 - 121.90
Shares Outstanding 63,525,838
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
13 Analysts Assess Blueprint Medicines: What You Need To Know
Via Benzinga
Breaking Down Blueprint Medicines: 10 Analysts Share Their Views
Via Benzinga

Performance

YTD
+4.17%
+4.17%
1 Month
-10.56%
-10.56%
3 Month
-1.88%
-1.88%
6 Month
+8.01%
+8.01%
1 Year
+0.26%
+0.26%

More News

Read More
Earnings Scheduled For February 13, 2025
Via Benzinga
Analyst Expectations For Blueprint Medicines's Future
Via Benzinga
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Via Benzinga
What Analysts Are Saying About Blueprint Medicines Stock
Via Benzinga
Is NASDAQ:BPMC a Fit for high Growth Investing Strategies?
Via Chartmill
Key Takeaways From Blueprint Medicines Analyst Ratings
Via Benzinga
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
Via Benzinga
Analyst Ratings For Blueprint Medicines
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
15 Analysts Have This To Say About Blueprint Medicines
Via Benzinga
Expert Ratings For Blueprint Medicines
Via Benzinga
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Unveiling 18 Analyst Insights On Blueprint Medicines
Via Benzinga
BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Via Benzinga
Decoding 6 Analyst Evaluations For Blueprint Medicines
Via Benzinga
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.